MULTIPLE MYELOMA AND OTHER PLASMA CELL DISEASES

multiplemyelomawos

FIRST LINE TREATMENTIN NEWLY DIAGNOSED TRANSPLANT INELIGIBLE MULTIPLE MYELOMA

Osman Can Öztürk1 Güner Hayri Özsan2

1Dokuz Eylül University, Research and Application Hospital, Department of Hematology, İzmir, Türkiye
2Dokuz Eylül University, Research and Application Hospital, Department of Hematology, İzmir, Türkiye

Öztürk OC, Özsan GH. First Line Treatment in Newly Diagnosed Transplant Ineligible Multiple Myeloma. In: Sevindik ÖG, editor. Multiple Myeloma and Other Plasma Cell Dyscrasias. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.45-54.

ABSTRACT

Multiple myeloma (MM) is a clonal malignant disease caused by monoclonal proliferation of plasma cells. MM comprises 13-17% of hematologic malignancies and known as a disease of advanced age. Induction followed by high-dose chemotherapy and consolidation with autologous stem cell transplantation remains the standard approach, even in the era of the new drugs. Therefore, the initial assessment of newly diagnosed MM patients is to determine whether they are candidates for autologous stem cell transplantation (ASCT). Management of Multiple Myeloma is rapidly evolving and combination of quadruplet and triplet treatment regimens are becoming standard of care for patients those not eligible for ASCT and contributes to the improvement of treatment responses, overall survival and progression-free survival in these patients.

Keywords: Multiple Myeloma; Treatment; Autologous bone marrow transplant

Referanslar

  1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: a cancer journal for clinicians. 2024;74(1). [Crossref]  [PubMed]
  2. Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC cancer. 2022;22(1):901. [Crossref]  [PubMed]  [PMC]
  3. Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. European journal of haematology. 2018;101(2):237-44. [Crossref]  [PubMed]  [PMC]
  4. Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. American journal of hematology. 2022;97:S3-S25. [Crossref]  [PubMed]
  5. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. Journal of clinical oncology. 2014;32(6):587-600. [Crossref]  [PubMed]  [PMC]
  6. Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36(3):801-8. [Crossref]  [PubMed]
  7. Explorer S. An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute Available online: statistics-network/explorer/application.html?site [Link]
  8. DuMontier C, Loh KP, Bain PA, Silliman RA, Hshieh T, Abel GA, et al. Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review. Journal of Clinical Oncology. 2020;38(22):2558-69. [Crossref]  [PubMed]  [PMC]
  9. Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. haematologica. 2017;102(5):910. [Crossref]  [PubMed]  [PMC]
  10. Palumbo A, Bringhen S, Mateos M-V, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood, The Journal of the American Society of Hematology. 2015;125(13):2068-74. [Crossref]  [PubMed]  [PMC]
  11. Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, et al. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. Journal of geriatric oncology. 2019;10(3):479-85. [Crossref]  [PubMed]  [PMC]
  12. Wildes TM, Tuchman SA, Klepin HD, Mikhael J, Trinkaus K, Stockerl-Goldstein K, et al. Geriatric assessment in older adults with multiple myeloma. Journal of the American Geriatrics Society. 2019;67(5):987-91. [Crossref]  [PubMed]  [PMC]
  13. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2001;56(3):M146-M57. [Crossref]  [PubMed]
  14. Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen W-M, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224-33. [Crossref]  [PubMed]  [PMC]
  15. Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American journal of hematology. 2016;91(11):1129-34. [Crossref]  [PubMed]  [PMC]
  16. Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC cancer. 2020;20:1-11. [Crossref]  [PubMed]  [PMC]
  17. Szabo AG, Iversen KF, Möller S, Plesner T. The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study. Clinical Hematology International. 2019;1(4):220-8. [Crossref]  [PubMed]  [PMC]
  18. Verelst SG, Blommestein HM, De Groot S, Gonzalez-McQuire S, DeCosta L, de Raad JB, et al. Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). Hemasphere. 2018;2(4):e45. [Crossref]  [PubMed]  [PMC]
  19. Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. British journal of haematology. 2016;175(2):252-64. [Crossref]  [PubMed]  [PMC]
  20. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. New England Journal of Medicine. 2014;371(10):906-17. [Crossref]  [PubMed]
  21. Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, The Journal of the American Society of Hematology. 2018;131(3):301-10. [Crossref]  [PubMed]  [PMC]
  22. Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, et al. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. Journal of Clinical Oncology. 2016;34(30):3609-17. [Crossref]  [PubMed]
  23. Durie BG, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood cancer journal. 2020;10(5):53. [Crossref]  [PubMed]  [PMC]
  24. O'Donnell EK, Laubach JP, Yee AJ, Redd R, Huff CA, Basile F, et al. Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma. Blood. 2019;134:3178. [Crossref]
  25. Facon T, Venner CP, Bahlis NJ, Offner F, White DJ, Karlin L, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood, The Journal of the American Society of Hematology. 2021;137(26):3616-28. [Crossref]  [PubMed]  [PMC]
  26. Mateos M-V, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. The Lancet. 2020;395(10218):132-41. [Crossref]  [PubMed]
  27. Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, et al. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Leukemia & lymphoma. 2022;63(10):2383-92. [Crossref]  [PubMed]
  28. Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. The Lancet Oncology. 2021;22(11):1582-96. [Crossref]  [PubMed]
  29. Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, et al. Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial. Journal of Clinical Oncology. 2021;39(3):227-37. [Crossref]  [PubMed]  [PMC]
  30. Blommestein HM, Franken MG, van Beurden-Tan CH, Blijlevens NM, Huijgens PC, Sonneveld P, et al. Cost-effectiveness of novel treatment sequences for transplant-ineligible patients with multiple myeloma. JAMA network open. 2021;4(3):e213497-e. [Crossref]  [PubMed]  [PMC]
  31. Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma. Journal of Clinical Oncology. 2021;39(10):1119-28. [Crossref]  [PubMed]
  32. Fonseca R, Facon T, Hashim M, Nair S, He J, Ammann E, et al. Impact of treatment sequencing on overall survival in patients with transplant-ineligible newly diagnosed myeloma. The oncologist. 2023;28(5):e263-e9. [Crossref]  [PubMed]  [PMC]
  33. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. American journal of hematology. 2024;99(9):1802-24. [Crossref]  [PubMed]
  34. Facon T, Dimopoulos M-A, Leleu XP, Beksac M, Pour L, Hájek R, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. 2024. [Crossref]  [PubMed]
  35. Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature Medicine. 2024:1-7.
  36. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, The Journal of the American Society of Hematology. 2016;127(24):2955-62. [Crossref]  [PubMed]  [PMC]
  37. Pawlyn C, Cairns D, Kaiser M, Striha A, Jones J, Shah V, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020;34(2):604-12. [Crossref]  [PubMed]  [PMC]
  38. Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA oncology. 2020;6(11):1759-65. [Crossref]  [PubMed]  [PMC]
  39. Burns EA, Ensor JE, Anand K, Gentille C, Guerrero C, Kieser RB, et al. Opportunistic infections in patients receiving daratumumab regimens for multiple myeloma (MM). Blood. 2021;138:4740. [Crossref]
  40. Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PloS one. 2019;14(2):e0211927. [Crossref]  [PubMed]  [PMC]
  41. Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M. Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. European journal of haematology. 2020;104(5):420-6. [Crossref]  [PubMed]
  42. Liu J, Li J, Shang J, Zheng D, Gu J, Zou W, et al. Observation of humoral immunity reconstitution and its relationship with infection after autologous hematopoietic stem cell transplantation for patients with multiple myeloma. Zhonghua xue ye xue za zhi= Zhonghua Xueyexue Zazhi. 2013;34(4):317-22. [Crossref]  [PubMed]
  43. Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31-44. [Crossref]  [PubMed]  [PMC]
  44. Dagnew AF, Ilhan O, Lee W-S, Woszczyk D, Kwak J-Y, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. The Lancet infectious diseases. 2019;19(9):988-1000. [Crossref]  [PubMed]
  45. Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M, editors. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Seminars in thrombosis and hemostasis; 2011: © Thieme Medical Publishers. [Crossref]  [PubMed]
  46. Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, et al. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood, The Journal of the American Society of Hematology. 2020;136(9):1091-104. [Crossref]  [PubMed]  [PMC]
  47. Palumbo A, Rajkumar S, Dimopoulos M, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-23. [Crossref]  [PubMed]
  48. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood advances. 2021;5(4):927-74. [Crossref]  [PubMed]  [PMC]
  49. Palumbo A, Bladé J, Boccadoro M, Palladino C, Davies F, Dimopoulos M, et al. How to manage neutropenia in multiple myeloma. Clinical Lymphoma Myeloma and Leukemia. 2012;12(1):5-11. [Crossref]  [PubMed]